Dobutamine Hydrochloride Injection

Adult administration

Adults: Administer by intravenous injection 2.5-10 μg/kg/min of dobutamine. In rare cases, infusion rates of 40 μg/kg/min may be necessary to achieve satisfactory effects. The dosage rate and treatment duration should be adjusted according to the patient's response, assessed by measuring heart rate, exercise displacement, blood pressure, urine output, central venous pressure, or pulmonary wedge pressure and cardiac output. Administrations have been made at concentrations up to 5,000 μg/mL (250 mg/50 mL).

This drug is an ampule injection, and care must be taken when breaking the glass container to avoid glass fragments from contaminating the solution, especially when administering to children or the elderly. This medication should not be administered to certain patients, including those with idiopathic hypertrophic subaortic stenosis, those with hypersensitivity to this drug or who have previously shown allergic reactions, patients with constrictive pericarditis or cardiac tamponade. Caution should be exercised when administering to patients with increased heart rate or blood pressure, severe coronary artery disease, atrial fibrillation, patients with ventricular dyskinesia, and severe hypotension due to cardiogenic shock. Due to the sodium bisulfite component in this drug, allergic reactions or asthma attacks may occur in some patients, so special caution is necessary for asthma sufferers. During use, rare hypersensitivity reactions such as skin rash, fever, bronchospasm, and cardiac-related side effects may occur, including rapid heart rate, arrhythmias, blood pressure elevation, angina symptoms, shortness of breath, and hypotension. Gastrointestinal side effects may include abdominal pain or nausea, and redness or swelling may occur at the injection site. Headaches can also occur, albeit infrequently. Continuous monitoring of blood pressure, heart rate, electrocardiograms, and urine output should be conducted during administration, and adequate vascular constrictor treatment may be necessary for patients with acute circulatory failure. Treatment to increase blood volume should be performed prior to administering this drug to patients with hypovolemia. Additionally, patients taking beta-blockers may experience reduced effects of this drug. This drug's safety has not been established for patients with acute myocardial infarction, and if heart rate and blood pressure increase excessively, dosage reduction measures may be necessary. Prolonged administration beyond 72 hours may result in tolerance, necessitating dose adjustments. Cautions should be taken when used in conjunction with certain vasodilators, beta-blockers, or MAO inhibitors, as interactions may occur. Women who are pregnant or of childbearing potential should only use this drug when the therapeutic benefits outweigh the risks, as its safety has not been established. If breastfeeding, consider avoiding administration or discontinuing nursing. The safety and efficacy of this drug have not been sufficiently evaluated in pediatric patients. Elderly patients may have diminished physiological functions, so administration should start at lower doses with careful observation of their condition. This drug is administered only via intravenous infusion, and care should be taken to prevent drug leakage outside the blood vessel, as local inflammation or tissue damage may occur at the injection site. When diluting, it should not be mixed with certain alkaline solutions or specific medications, and should be used within 24 hours of preparation. In cases of overdose, changes in blood pressure or rapid heart rate may occur, necessitating cessation of administration or dose reduction until the patient's condition stabilizes. This drug has a short duration of action, often not requiring additional treatments.

Serious side effects

Shortness of breath, bronchospasm (possible allergic reaction)

Mild side effects

• Rash
• fever
• eosinophilia
• bronchospasm
• tachycardia
• ectopic beats
• excessive blood pressure elevation
• angina
• precordial warmth
• chest discomfort

This drug should be stored in a sealed container to protect it from air exposure, preferably kept away from direct sunlight and at room temperature. Room temperature typically refers to a range between 15 to 25 degrees Celsius, and extremes should be avoided.

Appearance

A colorless to pale yellow transparent liquid or a colorless transparent ampule injection.

Package unit

1 ampule (5mL) X 50 ampules